BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Peng SY, Chen WJ, Lai PL, Jeng YM, Sheu JC, Hsu HC. High alpha-fetoprotein level correlates with high stage, early recurrence and poor prognosis of hepatocellular carcinoma: significance of hepatitis virus infection, age, p53 and beta-catenin mutations. Int J Cancer. 2004;112:44-50. [PMID: 15305374 DOI: 10.1002/ijc.20279] [Cited by in Crossref: 203] [Cited by in F6Publishing: 203] [Article Influence: 11.3] [Reference Citation Analysis]
Number Citing Articles
1 Ma L, Deng K, Zhang C, Li H, Luo Y, Yang Y, Li C, Li X, Geng Z, Xie C. Nomograms for Predicting Hepatocellular Carcinoma Recurrence and Overall Postoperative Patient Survival. Front Oncol 2022;12:843589. [PMID: 35296018 DOI: 10.3389/fonc.2022.843589] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
2 Xu C, Xu Z, Zhang Y, Evert M, Calvisi DF, Chen X. β-Catenin signaling in hepatocellular carcinoma. J Clin Invest 2022;132:e154515. [PMID: 35166233 DOI: 10.1172/JCI154515] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
3 Huang L, Songyang Z, Dai Z, Xiong Y. Field cancerization profile-based prognosis signatures lead to more robust risk evaluation in hepatocellular carcinoma. iScience 2022;25:103747. [DOI: 10.1016/j.isci.2022.103747] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Cuesta-Sancho S, Márquez-Coello M, Illanes-Álvarez F, Márquez-Ruiz D, Arizcorreta A, Galán-Sánchez F, Montiel N, Rodriguez-Iglesias M, Girón-González JA. Hepatitis C: Problems to extinction and residual hepatic and extrahepatic lesions after sustained virological response. World J Hepatol 2022; 14(1): 62-79 [DOI: 10.4254/wjh.v14.i1.62] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Hu X, Chen R, Wei Q, Xu X. The Landscape Of Alpha Fetoprotein In Hepatocellular Carcinoma: Where Are We? Int J Biol Sci 2022;18:536-51. [PMID: 35002508 DOI: 10.7150/ijbs.64537] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
6 Sun L, Cen W, Tang W, Deng L, Wang F, Ji X, Yang J, Zhang R, Zhang X, Du Z, Mei J. Alpha-Fetoprotein Ratio Predicts Alpha-Fetoprotein Positive Hepatocellular Cancer Patient Prognosis after Hepatectomy. Disease Markers 2022;2022:1-9. [DOI: 10.1155/2022/7640560] [Reference Citation Analysis]
7 Wu C, Luo Y, Chen Y, Qu H, Zheng L, Yao J. Development of a prognostic gene signature for hepatocellular carcinoma. Cancer Treat Res Commun 2022;31:100511. [PMID: 35030478 DOI: 10.1016/j.ctarc.2022.100511] [Reference Citation Analysis]
8 Xu J, Hong J, Wang Y, Zhou L, Xu B, Si Y, He Y, Chen Y. Prognostic Influence of Spontaneous Tumor Rupture in Patients With Hepatocellular Carcinoma After Hepatectomy: A Meta-Analysis of Observational Studies. Front Surg 2021;8:769233. [PMID: 34869566 DOI: 10.3389/fsurg.2021.769233] [Reference Citation Analysis]
9 She WH, Chan MY, Ma KW, Tsang SHY, Dai WC, Chan ACY, Lo CM, Cheung TT. Alpha-Fetoprotein in Predicting Survival of Patients with Ruptured Hepatocellular Carcinoma after Resection. J Invest Surg 2021;:1-7. [PMID: 34865574 DOI: 10.1080/08941939.2021.2012615] [Reference Citation Analysis]
10 Lee WC. Value of alpha-fetoprotein in hepatocellular carcinoma. Transl Gastroenterol Hepatol 2021;6:52. [PMID: 34805574 DOI: 10.21037/tgh.2019.12.19] [Reference Citation Analysis]
11 Jearth V, Patil PS, Mehta S, Sundaram S, Seth V, Goel M, Patkar S, Bal M, Rao V. Correlation of Clinicopathological Profile, Prognostic Factors, and Survival Outcomes with Baseline Alfa-Fetoprotein Levels in Patients With Hepatocellular Carcinoma: A Biomarker that is Bruised but Not Broken. Journal of Clinical and Experimental Hepatology 2021. [DOI: 10.1016/j.jceh.2021.11.006] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
12 Xu Y, Guo Q, Wei L. The Emerging Influences of Alpha-Fetoprotein in the Tumorigenesis and Progression of Hepatocellular Carcinoma. Cancers (Basel) 2021;13:5096. [PMID: 34680245 DOI: 10.3390/cancers13205096] [Reference Citation Analysis]
13 Cohen O, Aleem M, Wolberink S, Perenyei MA. Giant pedunculated liver mass: primary hepatocellular carcinoma masquerading as hepatic haemangioma. BMJ Case Rep 2021;14:e242625. [PMID: 34593547 DOI: 10.1136/bcr-2021-242625] [Reference Citation Analysis]
14 Zhang D, Wei Q, Wu GG, Zhang XY, Lu WW, Lv WZ, Liao JT, Cui XW, Ni XJ, Dietrich CF. Preoperative Prediction of Microvascular Invasion in Patients With Hepatocellular Carcinoma Based on Radiomics Nomogram Using Contrast-Enhanced Ultrasound. Front Oncol 2021;11:709339. [PMID: 34557410 DOI: 10.3389/fonc.2021.709339] [Reference Citation Analysis]
15 Lee JC, Hung HC, Wang YC, Cheng CH, Wu TH, Lee CF, Wu TJ, Chou HS, Chan KM, Lee WC. Risk Score Model for Microvascular Invasion in Hepatocellular Carcinoma: The Role of Tumor Burden and Alpha-Fetoprotein. Cancers (Basel) 2021;13:4403. [PMID: 34503212 DOI: 10.3390/cancers13174403] [Reference Citation Analysis]
16 Kotiyal S, Evason KJ. Exploring the Interplay of Telomerase Reverse Transcriptase and β-Catenin in Hepatocellular Carcinoma. Cancers (Basel) 2021;13:4202. [PMID: 34439356 DOI: 10.3390/cancers13164202] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 He F, Song K, Guan G, Huo J, Xin Y, Li T, Liu C, Zhu Q, Fan N, Guo Y, Wu L. The Phenomenon of Gene Rearrangement is Frequently Associated with TP53 Mutations and Poor Disease-Free Survival in Hepatocellular Carcinoma. Pharmgenomics Pers Med 2021;14:723-36. [PMID: 34188519 DOI: 10.2147/PGPM.S313848] [Reference Citation Analysis]
18 Chan A, Zhang WY, Chok K, Dai J, Ji R, Kwan C, Man N, Poon R, Lo CM. ALPPS Versus Portal Vein Embolization for Hepatitis-related Hepatocellular Carcinoma: A Changing Paradigm in Modulation of Future Liver Remnant Before Major Hepatectomy. Ann Surg 2021;273:957-65. [PMID: 31305284 DOI: 10.1097/SLA.0000000000003433] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 15.0] [Reference Citation Analysis]
19 Qin C, Gao Y, Li J, Huang C, He S. Predictive effects of preoperative serum CA125 and AFP levels on post-hepatectomy survival in patients with hepatitis B-related hepatocellular carcinoma. Oncol Lett 2021;21:487. [PMID: 33968203 DOI: 10.3892/ol.2021.12748] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
20 Shyrokova EY, Prassolov VS, Spirin PV. The Role of the MCTS1 and DENR Proteins in Regulating the Mechanisms Associated with Malignant Cell Transformation. Acta Naturae 2021;13:98-105. [PMID: 34377560 DOI: 10.32607/actanaturae.11181] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 O'Brien B. Developments in Hepatocellular Cancer Treatment. J Adv Pract Oncol 2021;12:310-4. [PMID: 34084581 DOI: 10.6004/jadpro.2021.12.3.19] [Reference Citation Analysis]
22 Delgado ER, Erickson HL, Tao J, Monga SP, Duncan AW, Anakk S. Scaffolding Protein IQGAP1 Is Dispensable, but Its Overexpression Promotes Hepatocellular Carcinoma via YAP1 Signaling. Mol Cell Biol 2021;41:e00596-20. [PMID: 33526450 DOI: 10.1128/MCB.00596-20] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Moldogazieva NT, Mokhosoev IM, Zavadskiy SP, Terentiev AA. Proteomic Profiling and Artificial Intelligence for Hepatocellular Carcinoma Translational Medicine. Biomedicines 2021;9:159. [PMID: 33562077 DOI: 10.3390/biomedicines9020159] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
24 Nadda N, Paul SB, Yadav DP, Kumar S, Sreenivas V, Saraya A, Gamanagatti S, Acharya SK, Shalimar, Nayak B. Prognostic and Therapeutic Potentials of OncomiRs Modulating mTOR Pathways in Virus-Associated Hepatocellular Carcinoma. Front Oncol 2020;10:604540. [PMID: 33614488 DOI: 10.3389/fonc.2020.604540] [Reference Citation Analysis]
25 Jensen C, Holm Nielsen S, Eslam M, Genovese F, Nielsen MJ, Vongsuvanh R, Uchila R, van der Poorten D, George J, Karsdal MA, Leeming DJ, Willumsen N. Cross-Linked Multimeric Pro-Peptides of Type III Collagen (PC3X) in Hepatocellular Carcinoma - A Biomarker That Provides Additional Prognostic Value in AFP Positive Patients. J Hepatocell Carcinoma 2020;7:301-13. [PMID: 33204663 DOI: 10.2147/JHC.S275008] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
26 Liu G, Xia F, Fan G, Yu J, Bao L, Zhang C, Chi R, Zhang T, Wang L, Shen F, Wang D. Type 2 diabetes mellitus worsens the prognosis of intermediate-stage hepatocellular carcinoma after transarterial chemoembolization. Diabetes Res Clin Pract 2020;169:108375. [PMID: 32827592 DOI: 10.1016/j.diabres.2020.108375] [Reference Citation Analysis]
27 Zhu G, Wang W, Liu Q, Chen D, Wen L. A Real-World Study of Prognosis of N0M0 Hepatocellular Carcinoma with Hepatic Resection Based on SEER Database. Gastroenterol Res Pract 2020;2020:2357840. [PMID: 32328093 DOI: 10.1155/2020/2357840] [Reference Citation Analysis]
28 Yousef EH, El-Mesery ME, Habeeb MR, Eissa LA. Polo-like kinase 1 as a promising diagnostic biomarker and potential therapeutic target for hepatocellular carcinoma. Tumour Biol 2020;42:1010428320914475. [PMID: 32252611 DOI: 10.1177/1010428320914475] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
29 Abdou AG, Holah NS, Elazab DS, El-Gendy WG, Badr MT, Al-Sharaky DR. Hepatocellular Carcinoma Score and Subclassification Into Aggressive Subtypes Using Immunohistochemical Expression of p53, β-Catenin, CD133, and Ki-67. Appl Immunohistochem Mol Morphol 2021;29:20-33. [PMID: 32287076 DOI: 10.1097/PAI.0000000000000840] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
30 Yang Z, Yang Y, Zhou G, Luo Y, Yang W, Zhou Y, Yang J. The Prediction of Survival in Hepatocellular Carcinoma Based on A Four Long Non-coding RNAs Expression Signature. J Cancer 2020;11:4132-44. [PMID: 32368296 DOI: 10.7150/jca.40621] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
31 Tang J, Sui CJ, Wang DF, Lu XY, Luo GJ, Zhao Q, Lian QY, Jeong S, Lin XM, Zhu YJ, Zheng B, Wu R, Wang Q, Liu XL, Liu JF, Xia Q, Wu G, Gu J, Wang HY, Chen L. Targeted sequencing reveals the mutational landscape responsible for sorafenib therapy in advanced hepatocellular carcinoma. Theranostics 2020;10:5384-97. [PMID: 32373219 DOI: 10.7150/thno.41616] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
32 Kim H, Lee SJ, Yoon M. Alpha-fetoprotein is correlated with intrahepatic recurrence of hepatocellular carcinoma after a hepatectomy. Ann Surg Treat Res 2020;98:168-76. [PMID: 32274364 DOI: 10.4174/astr.2020.98.4.168] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
33 Morio K, Kawaoka T, Aikata H, Namba M, Uchikawa S, Kodama K, Ohya K, Fujino H, Nakahara T, Murakami E, Yamauchi M, Tsuge M, Hiramatsu A, Imamura M, Nakamura Y, Akagi M, Awai K, Kobayashi T, Ohdan H, Chayama K. Preoperative PET-CT is useful for predicting recurrent extrahepatic metastasis of hepatocellular carcinoma after resection. Eur J Radiol. 2020;124:108828. [PMID: 31955034 DOI: 10.1016/j.ejrad.2020.108828] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
34 Chen W, Peng J, Ye J, Dai W, Li G, He Y. Aberrant AFP expression characterizes a subset of hepatocellular carcinoma with distinct gene expression patterns and inferior prognosis. J Cancer 2020;11:403-13. [PMID: 31897235 DOI: 10.7150/jca.31435] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
35 Chuang YH, Ou HY, Yu CY, Chen CL, Weng CC, Tsang LL, Hsu HW, Lim WX, Huang TL, Cheng YF. Diffusion-weighted imaging for identifying patients at high risk of tumor recurrence following liver transplantation. Cancer Imaging 2019;19:74. [PMID: 31730015 DOI: 10.1186/s40644-019-0264-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
36 Paul SB, Sahu P, Sreenivas V, Nadda N, Gamanagatti SR, Nayak B, Shalimar S, Acharya SK. Prognostic role of serial alpha-fetoprotein levels in hepatocellular carcinoma treated with locoregional therapy. Scand J Gastroenterol 2019;54:1132-7. [PMID: 31483691 DOI: 10.1080/00365521.2019.1660403] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
37 Chang Y, Cho Y, Lee JH, Lee YB, Cho EJ, Yu SJ, Sinn DH, Kim BH, Kim SH, Yi NJ, Lee KW, Kim JM, Park JW, Kim YJ, Yoon JH, Joh JW, Suh KS. Comparison of Models for Tumor Recurrence after Liver Transplantation for the Patients with Hepatocellular Carcinoma: A Multicenter Long-Term Follow-Up Study. Cancers (Basel) 2019;11:E1295. [PMID: 31484287 DOI: 10.3390/cancers11091295] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
38 Shao YY, Liu TH, Hsu C, Lu LC, Shen YC, Lin ZZ, Cheng AL, Hsu CH. Early alpha-foetoprotein response associated with treatment efficacy of immune checkpoint inhibitors for advanced hepatocellular carcinoma. Liver Int. 2019;39:2184-2189. [PMID: 31400295 DOI: 10.1111/liv.14210] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
39 Halazun KJ, Tabrizian P, Najjar M, Florman S, Schwartz M, Michelassi F, Samstein B, Brown RS, Emond JC, Busuttil RW, Agopian VG. Is it Time to Abandon the Milan Criteria?: Results of a Bicoastal US Collaboration to Redefine Hepatocellular Carcinoma Liver Transplantation Selection Policies. Ann Surg. 2018;268:690-699. [PMID: 30048307 DOI: 10.1097/sla.0000000000002964] [Cited by in Crossref: 34] [Cited by in F6Publishing: 15] [Article Influence: 11.3] [Reference Citation Analysis]
40 Lin HH, Peng YJ, Tsai MJ, Wu YY, Tsai TN, Huang HH, Shih YL, Chang WK, Hsieh TY. Upregulation of amphiregulin by retinoic acid and Wnt signalling promotes liver cancer cell proliferation. J Cell Physiol 2020;235:1689-99. [PMID: 31298420 DOI: 10.1002/jcp.29088] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
41 Mahmud N, John B, Taddei TH, Goldberg DS. Pre-transplant alpha-fetoprotein is associated with post-transplant hepatocellular carcinoma recurrence mortality. Clin Transplant. 2019;33:e13634. [PMID: 31177570 DOI: 10.1111/ctr.13634] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
42 Wang S, Gribskov M. Transcriptome analysis identifies metallothionein as biomarkers to predict recurrence in hepatocellular cacinoma. Mol Genet Genomic Med 2019;7:e693. [PMID: 31056863 DOI: 10.1002/mgg3.693] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
43 Brodeur CM, Thibault P, Durand M, Perreault JP, Bisaillon M. Dissecting the expression landscape of cytochromes P450 in hepatocellular carcinoma: towards novel molecular biomarkers. Genes Cancer 2019;10:97-108. [PMID: 31258835 DOI: 10.18632/genesandcancer.190] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
44 Lee JC, Cheng CH, Wang YC, Wu TH, Lee CF, Wu TJ, Chou HS, Chan KM, Lee WC. Clinical relevance of alpha-fetoprotein in determining resection margin for hepatocellular carcinoma. Medicine (Baltimore) 2019;98:e14827. [PMID: 30882667 DOI: 10.1097/MD.0000000000014827] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
45 Lee WC, Wang YC, Cheng CH, Wu TH, Lee CF, Wu TJ, Chou HS, Chan KM. Myeloid-derived suppressor cells in the patients with liver resection for hepatitis B virus-related hepatocellular carcinoma. Sci Rep 2019;9:2269. [PMID: 30783140 DOI: 10.1038/s41598-019-38785-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
46 Gurakar A, Ma M, Garonzik-wang J, Kim A, Anders RA, Oshima K, Georgiades C, Gurakar M, Ottmann S, Cameron AM, Philosophe B, Saberi B. Clinicopathological Distinction of Low-AFP-Secreting vs. High-AFP-Secreting Hepatocellular Carcinomas. Annals of Hepatology 2018;17:1052-66. [DOI: 10.5604/01.3001.0012.7206] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
47 Shen J, Li C, Yan L, Li B, Xu M, Yang J, Wang W, Wen T. Short- and Long-term Outcomes between Young and Older HCC Patients Exceeding The Milan Criteria after Hepatectomy. Ann Hepatol 2018;17:134-43. [PMID: 29311397 DOI: 10.5604/01.3001.0010.7545] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
48 Abdelghany AM, Rezk NS, Osman MM, Hamid AI, Al-Breedy AM, Abdelsattar HA. Using Lamin B1 mRNA for the early diagnosis of hepatocellular carcinoma: a cross-sectional diagnostic accuracy study. F1000Res 2018;7:1339. [PMID: 30467522 DOI: 10.12688/f1000research.14795.1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
49 Wang M, Yuan F, Wei Y, Xia C, Hu F, Song B. Hepatocellular Carcinoma: In Vivo Evaluation of Water Percentage as a Prognostic Biomarker Using Magnetic Resonance Imaging 3D-VIBE Multiecho Dixon. Cancer Biother Radiopharm 2018;33:300-6. [PMID: 30109954 DOI: 10.1089/cbr.2018.2483] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
50 Liu G, Ouyang Q, Xia F, Fan G, Yu J, Zhang C, Wang D. Alpha-fetoprotein response following transarterial chemoembolization indicates improved survival for intermediate-stage hepatocellular carcinoma. HPB (Oxford). 2019;21:107-113. [PMID: 30017783 DOI: 10.1016/j.hpb.2018.06.1800] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
51 Khalaf AM, Fuentes D, Morshid AI, Burke MR, Kaseb AO, Hassan M, Hazle JD, Elsayes KM. Role of Wnt/β-catenin signaling in hepatocellular carcinoma, pathogenesis, and clinical significance. J Hepatocell Carcinoma 2018;5:61-73. [PMID: 29984212 DOI: 10.2147/JHC.S156701] [Cited by in Crossref: 68] [Cited by in F6Publishing: 44] [Article Influence: 17.0] [Reference Citation Analysis]
52 Huang X, Xiao Z, Zhang Y, Lin N, Xiong M, Huang X, Chen Q, Cao D. Hepatocellular Carcinoma: Retrospective Evaluation of the Correlation Between Gadobenate Dimeglumine-Enhanced Magnetic Resonance Imaging and Pathologic Grade. J Comput Assist Tomogr 2018;42:365-72. [PMID: 29369947 DOI: 10.1097/RCT.0000000000000707] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
53 Lersritwimanmaen P, Nimanong S. Hepatocellular Carcinoma Surveillance: Benefit of Serum Alfa-fetoprotein in Real-world Practice. Euroasian J Hepatogastroenterol 2018;8:83-7. [PMID: 29963472 DOI: 10.5005/jp-journals-10018-1268] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
54 Fang Y, He J, Janssen HL, Wu J, Dong L, Shen XZ. Peroxiredoxin 1, restraining cell migration and invasion, is involved in hepatocellular carcinoma recurrence. Journal of Digestive Diseases 2018;19:155-69. [DOI: 10.1111/1751-2980.12580] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
55 Afshar M, Fletcher P, Bardoli AD, Ma YT, Punia P. Non-secretion of AFP and neutrophil lymphocyte ratio as predictors for survival in hepatocellular carcinoma patients treated with sorafenib: a large UK cohort. Oncotarget 2018;9:16988-95. [PMID: 29682199 DOI: 10.18632/oncotarget.24769] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
56 Kancherla V, Abdullazade S, Matter MS, Lanzafame M, Quagliata L, Roma G, Hoshida Y, Terracciano LM, Ng CKY, Piscuoglio S. Genomic Analysis Revealed New Oncogenic Signatures in TP53-Mutant Hepatocellular Carcinoma. Front Genet 2018;9:2. [PMID: 29456550 DOI: 10.3389/fgene.2018.00002] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
57 Yang X, Guo X, Chen Y, Chen G, Ma Y, Huang K, Zhang Y, Zhao Q, Winkler CA, An P. Telomerase reverse transcriptase promoter mutations in hepatitis B virus-associated hepatocellular carcinoma. Oncotarget. 2016;7:27838-27847. [PMID: 27056898 DOI: 10.18632/oncotarget.8539] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
58 Huang XQ, Zhou ZQ, Zhang XF, Chen CL, Tang Y, Zhu Q, Zhang JH, Xia JC. Overexpression of SMOC2 Attenuates the Tumorigenicity of Hepatocellular Carcinoma Cells and Is Associated With a Positive Postoperative Prognosis in Human Hepatocellular Carcinoma. J Cancer 2017;8:3812-27. [PMID: 29151969 DOI: 10.7150/jca.20775] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
59 Ni Q, Chen J, Li X, Xu X, Zhang N, Zhou A, Zhou B, Lu Q, Chen Z. Expression of OTUB1 in hepatocellular carcinoma and its effects on HCC cell migration and invasion. Acta Biochim Biophys Sin (Shanghai) 2017;49:680-8. [PMID: 28575188 DOI: 10.1093/abbs/gmx056] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
60 He B, Yin J, Gong S, Gu J, Xiao J, Shi W, Ding W, He Y. Bioinformatics analysis of key genes and pathways for hepatocellular carcinoma transformed from cirrhosis. Medicine (Baltimore) 2017;96:e6938. [PMID: 28640074 DOI: 10.1097/MD.0000000000006938] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
61 Carotenuto P, Fassan M, Pandolfo R, Lampis A, Vicentini C, Cascione L, Paulus-Hock V, Boulter L, Guest R, Quagliata L, Hahne JC, Ridgway R, Jamieson T, Athineos D, Veronese A, Visone R, Murgia C, Ferrari G, Guzzardo V, Evans TRJ, MacLeod M, Feng GJ, Dale T, Negrini M, Forbes SJ, Terracciano L, Scarpa A, Patel T, Valeri N, Workman P, Sansom O, Braconi C. Wnt signalling modulates transcribed-ultraconserved regions in hepatobiliary cancers. Gut 2017;66:1268-77. [PMID: 27618837 DOI: 10.1136/gutjnl-2016-312278] [Cited by in Crossref: 50] [Cited by in F6Publishing: 45] [Article Influence: 10.0] [Reference Citation Analysis]
62 Halazun KJ, Najjar M, Abdelmessih RM, Samstein B, Griesemer AD, Guarrera JV, Kato T, Verna EC, Emond JC, Brown RS. Recurrence After Liver Transplantation for Hepatocellular Carcinoma: A New MORAL to the Story. Ann Surg. 2017;265:557-564. [PMID: 27611615 DOI: 10.1097/sla.0000000000001966] [Cited by in Crossref: 108] [Cited by in F6Publishing: 49] [Article Influence: 21.6] [Reference Citation Analysis]
63 Woo JH, Song KD, Kim SH. Subcentimeter hypervascular nodules with typical imaging findings of hepatocellular carcinoma on gadoxetic acid-enhanced MRI: Outcomes of early treatment and watchful waiting. Eur Radiol. 2017;27:4406-4414. [PMID: 28386720 DOI: 10.1007/s00330-017-4818-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
64 Xu X, Chen J, Wang F, Ni Q, Naimat U, Chen Z. Recurrence of Hepatocellular Carcinoma After Laparoscopic Hepatectomy: Risk Factors and Treatment Strategies. J Laparoendosc Adv Surg Tech A 2017;27:676-84. [PMID: 28326886 DOI: 10.1089/lap.2016.0541] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
65 Kato K, Abe H, Ika M, Yonezawa T, Sato Y, Hanawa N, Shimizu S, Endo S, Matsuo R, Tsubota A. C-Arm Cone Beam Computed Tomography Guidance for Radiofrequency Ablation in Hepatocellular Carcinoma. Oncology. 2017;92:142-152. [PMID: 28052301 DOI: 10.1159/000453665] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
66 Kim SH, Moon DB, Kim WJ, Kang WH, Kwon JH, Jwa EK, Cho HD, Ha SM, Chung YK, Lee SG. Preoperative prognostic values of α-fetoprotein (AFP) and protein induced by vitamin K absence or antagonist-II (PIVKA-II) in patients with hepatocellular carcinoma for living donor liver transplantation. Hepatobiliary Surg Nutr 2016;5:461-9. [PMID: 28124000 DOI: 10.21037/hbsn.2016.11.05] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
67 Rhee WJ, Hwang SH, Byun HK, Yun M, Han KH, Seong J. Risk stratification for locally advanced hepatocellular carcinoma using pretreatment alpha-foetoprotein and 18 F-fluoro-2-deoxyglucose positron emission tomography. Liver Int. 2017;37:592-599. [PMID: 27804192 DOI: 10.1111/liv.13297] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
68 Sasaki M, Sato Y, Nakanuma Y. Mutational landscape of combined hepatocellular carcinoma and cholangiocarcinoma, and its clinicopathological significance. Histopathology 2017;70:423-34. [PMID: 27634656 DOI: 10.1111/his.13084] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 5.5] [Reference Citation Analysis]
69 Jung YK, Jung CH, Seo YS, Kim JH, Kim TH, Yoo YJ, Kang SH, Yim SY, Suh SJ, An H, Yim HJ, Yeon JE, Byun KS, Um SH. BCLC stage B is a better designation for single large hepatocellular carcinoma than BCLC stage A. J Gastroenterol Hepatol 2016;31:467-74. [PMID: 26332049 DOI: 10.1111/jgh.13152] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 4.5] [Reference Citation Analysis]
70 Lequoy M, Desbois-mouthon C, Wendum D, Gupta V, Blachon J, Scatton O, Dumont S, Bonnemaire M, Schmidlin F, Rosmorduc O, Fartoux L. Somatostatin receptors in resected hepatocellular carcinoma: status and correlation with markers of poor prognosis. Histopathology 2017;70:492-8. [DOI: 10.1111/his.13034] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
71 Hanafy AS. Efficacy of low dose capecitabine and sorafenib in patients with advanced alfa-fetoprotein secreting hepatocellular carcinoma: a 1 year experience. Springerplus 2016;5:1675. [PMID: 27733977 DOI: 10.1186/s40064-016-3376-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
72 Shen JY, Li C, Wen TF, Yan LN, Li B, Wang WT, Yang JY, Xu MQ. Alpha fetoprotein changes predict hepatocellular carcinoma survival beyond the Milan criteria after hepatectomy. J Surg Res. 2017;209:102-111. [PMID: 28032546 DOI: 10.1016/j.jss.2016.10.005] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 2.5] [Reference Citation Analysis]
73 Sauzay C, Petit A, Bourgeois AM, Barbare JC, Chauffert B, Galmiche A, Houessinon A. Alpha-foetoprotein (AFP): A multi-purpose marker in hepatocellular carcinoma. Clin Chim Acta. 2016;463:39-44. [PMID: 27732875 DOI: 10.1016/j.cca.2016.10.006] [Cited by in Crossref: 91] [Cited by in F6Publishing: 94] [Article Influence: 15.2] [Reference Citation Analysis]
74 Zhang XF, Chao J, Pan QZ, Pan K, Weng DS, Wang QJ, Zhao JJ, He J, Liu Q, Jiang SS, Chen CL, Zhang HX, Xia JC. Overexpression of WWP1 promotes tumorigenesis and predicts unfavorable prognosis in patients with hepatocellular carcinoma. Oncotarget 2015;6:40920-33. [PMID: 26506518 DOI: 10.18632/oncotarget.5712] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.7] [Reference Citation Analysis]
75 Liao W, Liu W, Liu X, Yuan Q, Ou Y, Qi Y, Huang W, Wang Y, Huang J. Upregulation of FAM83D affects the proliferation and invasion of hepatocellular carcinoma. Oncotarget 2015;6:24132-47. [PMID: 26125229 DOI: 10.18632/oncotarget.4432] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 4.0] [Reference Citation Analysis]
76 Kim YI, Kim HS, Park JW. Higher Ratio of Serum Alpha-Fetoprotein Could Predict Outcomes in Patients with Hepatitis B Virus-Associated Hepatocellular Carcinoma and Normal Alanine Aminotransferase. PLoS One. 2016;11:e0157299. [PMID: 27304617 DOI: 10.1371/journal.pone.0157299] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
77 Lin YF, Li LH, Lin CH, Tsou MH, Chuang MT, Wu KM, Liao TL, Li JC, Wang WJ, Tomita A, Tomita B, Huang SF, Tsai SF. Selective Retention of an Inactive Allele of the DKK2 Tumor Suppressor Gene in Hepatocellular Carcinoma. PLoS Genet 2016;12:e1006051. [PMID: 27203079 DOI: 10.1371/journal.pgen.1006051] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
78 Xu X, Qu K, Pang Q, Wang Z, Zhou Y, Liu C. Association between telomere length and survival in cancer patients: a meta-analysis and review of literature. Front Med 2016;10:191-203. [PMID: 27185042 DOI: 10.1007/s11684-016-0450-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
79 Liu G, Wang K, Li J, Xia Y, Lu L, Wan X, Yan Z, Shi L, Lau WY, Wu M, Shen F. Changes in serum alpha fetoprotein in patients with recurrent hepatocellular carcinoma following hepatectomy. J Gastroenterol Hepatol. 2015;30:1405-1411. [PMID: 25801981 DOI: 10.1111/jgh.12953] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
80 Xu XS, Chen W, Miao RC, Zhou YY, Wang ZX, Zhang LQ, Qu K, Pang Q, Wang RT, Liu C. Survival Analysis of Hepatocellular Carcinoma: A Comparison Between Young Patients and Aged Patients. Chin Med J (Engl) 2015;128:1793-800. [PMID: 26112722 DOI: 10.4103/0366-6999.159356] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
81 Gao R, Cai C, Gan J, Yang X, Shuang Z, Liu M, Li S, Tang H. miR-1236 down-regulates alpha-fetoprotein, thus causing PTEN accumulation, which inhibits the PI3K/Akt pathway and malignant phenotype in hepatoma cells. Oncotarget 2015;6:6014-28. [PMID: 25714026 DOI: 10.18632/oncotarget.3338] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 5.3] [Reference Citation Analysis]
82 Della Corte C, Triolo M, Iavarone M, Sangiovanni A. Early diagnosis of liver cancer: an appraisal of international recommendations and future perspectives. Liver Int 2016;36:166-76. [PMID: 26386254 DOI: 10.1111/liv.12965] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
83 Hu L, Xue F, Li Y, Shao M, Sun Y, Wei G. A long-term follow-up and comprehensive observation of risk and prognosis factors of recurrence and survival after resection of hepatocellular carcinoma. Cell Biochem Biophys 2014;69:421-31. [PMID: 24728944 DOI: 10.1007/s12013-013-9813-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
84 Ette AI, Ndububa DA, Adekanle O, Ekrikpo U. Utility of serum des-gamma-carboxyprothrombin in the diagnosis of hepatocellular carcinoma among Nigerians, a case-control study. BMC Gastroenterol 2015;15:113. [PMID: 26341083 DOI: 10.1186/s12876-015-0344-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
85 Liao W, Huang G, Liao Y, Yang J, Chen Q, Xiao S, Jin J, He S, Wang C. High KIF18A expression correlates with unfavorable prognosis in primary hepatocellular carcinoma. Oncotarget 2014;5:10271-9. [PMID: 25431949 DOI: 10.18632/oncotarget.2082] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 4.4] [Reference Citation Analysis]
86 Wang Q, Luan W, Warren L, Fiel MI, Blank S, Kadri H, Tuvin D, Hiotis SP. Serum hepatitis B surface antigen correlates with tissue covalently closed circular DNA in patients with hepatitis B-associated hepatocellular carcinoma: HBsAg in HBV-HCC. J Med Virol 2016;88:244-51. [DOI: 10.1002/jmv.24326] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
87 Jin H, Zhang Y, You H, Tao X, Wang C, Jin G, Wang N, Ruan H, Gu D, Huo X, Cong W, Qin W. Prognostic significance of kynurenine 3-monooxygenase and effects on proliferation, migration, and invasion of human hepatocellular carcinoma. Sci Rep 2015;5:10466. [PMID: 26099564 DOI: 10.1038/srep10466] [Cited by in Crossref: 33] [Cited by in F6Publishing: 36] [Article Influence: 4.7] [Reference Citation Analysis]
88 Uygun Ilikhan S, Bilici M, Sahin H, Demir Akca AS, Can M, Oz II, Guven B, Buyukuysal MC, Ustundag Y. Assessment of the correlation between serum prolidase and alpha-fetoprotein levels in patients with hepatocellular carcinoma. World J Gastroenterol 2015; 21(22): 6999-7007 [PMID: 26078578 DOI: 10.3748/wjg.v21.i22.6999] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 22] [Article Influence: 3.4] [Reference Citation Analysis]
89 Li G, Yuan L, Liu D, Liu J. Upregulation of Leucine Zipper Protein mRNA in Hepatocellular Carcinoma Associated With Poor Prognosis. Technol Cancer Res Treat 2016;15:517-22. [PMID: 26031464 DOI: 10.1177/1533034615587432] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
90 Gomaa AI, Al-Khatib A, Abdel-Razek W, Hashim MS, Waked I. Ascites and alpha-fetoprotein improve prognostic performance of Barcelona Clinic Liver Cancer staging. World J Gastroenterol 2015; 21(18): 5654-5662 [PMID: 25987792 DOI: 10.3748/wjg.v21.i18.5654] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
91 Huang WJ, Jeng YM, Lai HS, Fong IU, Sheu FY, Lai PL, Yuan RH. Expression of hypoxic marker carbonic anhydrase IX predicts poor prognosis in resectable hepatocellular carcinoma. PLoS One 2015;10:e0119181. [PMID: 25738958 DOI: 10.1371/journal.pone.0119181] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
92 Wahab MA, Shehta A, Hamed H, El Nakeeb A, Salah T. Predictors of recurrence in hepatitis C virus related hepatocellular carcinoma after hepatic resection: a retrospective cohort study. Eurasian J Med 2014;46:36-41. [PMID: 25610292 DOI: 10.5152/eajm.2014.07] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
93 Takaki H, Yamakado K, Tsurusaki M, Yasumoto T, Baba Y, Narimatsu Y, Shimohira M, Yamaguchi M, Matsuo K, Inaba Y. Hepatic arterial infusion chemotherapy with fine-powder cisplatin and iodized-oil suspension in patients with intermediate-stage and advanced-stage (Barcelona Clinic Liver Cancer stage-B or stage-C) hepatocellular carcinoma: multicenter phase-II clinical study. Int J Clin Oncol. 2015;20:745-754. [PMID: 25432660 DOI: 10.1007/s10147-014-0773-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
94 Blank S, Wang Q, Fiel MI, Luan W, Kim KW, Kadri H, Mandeli J, Hiotis SP. Assessing prognostic significance of preoperative alpha-fetoprotein in hepatitis B-associated hepatocellular carcinoma: normal is not the new normal. Ann Surg Oncol. 2014;21:986-994. [PMID: 24232510 DOI: 10.1245/s10434-013-3357-z] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 3.4] [Reference Citation Analysis]
95 Yasui D, Murata S, Onozawa S, Mine T, Ueda T, Sugihara F, Kawamoto C, Uchida E, Kumita S. Improved efficacy of transcatheter arterial chemoembolization using warmed miriplatin for hepatocellular carcinoma. Biomed Res Int 2014;2014:359296. [PMID: 25276780 DOI: 10.1155/2014/359296] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
96 Yuan R, Lai H, Hsu H, Lai P, Jeng Y. Expression of Bile Duct Transcription Factor HNF1β Predicts Early Tumor Recurrence and Is a Stage-Independent Prognostic Factor in Hepatocellular Carcinoma. J Gastrointest Surg 2014;18:1784-94. [DOI: 10.1007/s11605-014-2596-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
97 Shao YY, Hsu CH, Cheng AL. Predictive biomarkers of antiangiogenic therapy for advanced hepatocellular carcinoma: where are we? Liver Cancer 2013;2:93-107. [PMID: 24159601 DOI: 10.1159/000343845] [Cited by in Crossref: 17] [Cited by in F6Publishing: 21] [Article Influence: 2.1] [Reference Citation Analysis]
98 Kwon SK, Yun SS, Kim HJ, Lee DS. The risk factors of early recurrence after hepatectomy in hepatocellular carcinoma. Ann Surg Treat Res 2014;86:283-8. [PMID: 24949318 DOI: 10.4174/astr.2014.86.6.283] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
99 Giannini EG, Sammito G, Farinati F, Ciccarese F, Pecorelli A, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Borzio F. Determinants of alpha-fetoprotein levels in patients with hepatocellular carcinoma: implications for its clinical use. Cancer. 2014;120:2150-2157. [PMID: 24723129 DOI: 10.1002/cncr.28706] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 4.0] [Reference Citation Analysis]
100 Nault JC. Molecular Determinants of Prognosis in Hepatocellular Carcinoma. J Clin Transl Hepatol 2014;2:31-6. [PMID: 26357615 DOI: 10.14218/JCTH.2013.00029] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
101 Gomaa AI, Hashim MS, Waked I. Comparing staging systems for predicting prognosis and survival in patients with hepatocellular carcinoma in Egypt. PLoS One 2014;9:e90929. [PMID: 24603710 DOI: 10.1371/journal.pone.0090929] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 5.1] [Reference Citation Analysis]
102 Allard MA, Sa Cunha A, Ruiz A, Vibert E, Sebagh M, Castaing D, Adam R. The postresection alpha-fetoprotein in cirrhotic patients with hepatocellular carcinoma. An independent predictor of outcome. J Gastrointest Surg. 2014;18:701-708. [PMID: 24402605 DOI: 10.1007/s11605-013-2433-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
103 Giannini EG, Cucchetti A, Erroi V, Garuti F, Odaldi F, Trevisani F. Surveillance for early diagnosis of hepatocellular carcinoma: How best to do it? World J Gastroenterol 2013; 19(47): 8808-8821 [PMID: 24379604 DOI: 10.3748/wjg.v19.i47.8808] [Cited by in CrossRef: 52] [Cited by in F6Publishing: 47] [Article Influence: 5.8] [Reference Citation Analysis]
104 Longo V, Brunetti O, D’oronzo S, Ostuni C, Gatti P, Silvestris F. Bone metastases in hepatocellular carcinoma: an emerging issue. Cancer Metastasis Rev 2014;33:333-42. [DOI: 10.1007/s10555-013-9454-4] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 2.3] [Reference Citation Analysis]
105 Xie C, Huang L, Xie S, Xie D, Zhang G, Wang P, Peng L, Gao Z. LARP1 predict the prognosis for early-stage and AFP-normal hepatocellular carcinoma. J Transl Med 2013;11:272. [PMID: 24159927 DOI: 10.1186/1479-5876-11-272] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 2.2] [Reference Citation Analysis]
106 Harimoto H, Shimizu M, Nakagawa Y, Nakatsuka K, Wakabayashi A, Sakamoto C, Takahashi H. Inactivation of tumor-specific CD8⁺ CTLs by tumor-infiltrating tolerogenic dendritic cells. Immunol Cell Biol 2013;91:545-55. [PMID: 24018532 DOI: 10.1038/icb.2013.38] [Cited by in Crossref: 48] [Cited by in F6Publishing: 52] [Article Influence: 5.3] [Reference Citation Analysis]
107 Hatzaras I, Bischof DA, Fahy B, Cosgrove D, Pawlik TM. Treatment options and surveillance strategies after therapy for hepatocellular carcinoma. Ann Surg Oncol 2014;21:758-66. [PMID: 24006095 DOI: 10.1245/s10434-013-3254-5] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 3.0] [Reference Citation Analysis]
108 Giannini EG, Savarino V. Predicting the posttransplant prognosis of patients with hepatocellular carcinoma: what lies beneath alpha-fetoprotein? Liver Transpl 2013;19:1166-7. [PMID: 23929508 DOI: 10.1002/lt.23717] [Reference Citation Analysis]
109 Wang Q, Fiel MI, Blank S, Luan W, Kadri H, Kim KW, Manizate F, Rosenblatt AG, Labow DM, Schwartz ME, Hiotis SP. Impact of liver fibrosis on prognosis following liver resection for hepatitis B-associated hepatocellular carcinoma. Br J Cancer 2013;109:573-81. [PMID: 23846171 DOI: 10.1038/bjc.2013.352] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
110 Park H, Kim SU, Park JY, Kim DY, Ahn SH, Chon CY, Han KH, Seong J. Clinical usefulness of double biomarkers AFP and PIVKA-II for subdividing prognostic groups in locally advanced hepatocellular carcinoma. Liver Int. 2014;34:313-321. [PMID: 23895043 DOI: 10.1111/liv.12274] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
111 Wang Q, Fiel MI, Blank S, Luan W, Kadri H, Kim KW, Manizate F, Rosenblatt AG, Labow DM, Schwartz ME. Impact of liver fibrosis on prognosis following liver resection for hepatitis B-associated hepatocellular carcinoma. Br J Cancer. 2013;109:573-581. [PMID: 23846171 DOI: 10.1038/bjc.2013.352] [Cited by in Crossref: 44] [Cited by in F6Publishing: 42] [Article Influence: 4.9] [Reference Citation Analysis]
112 Yuan RH, Chang KT, Chen YL, Hsu HC, Lee PH, Lai PL, Jeng YM. S100P expression is a novel prognostic factor in hepatocellular carcinoma and predicts survival in patients with high tumor stage or early recurrent tumors. PLoS One. 2013;8:e65501. [PMID: 23785431 DOI: 10.1371/journal.pone.0065501] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 1.8] [Reference Citation Analysis]
113 Chen YL, Chen CH, Hu RH, Ho MC, Jeng YM. Elevated preoperative serum CA19-9 levels in patients with hepatocellular carcinoma is associated with poor prognosis after resection. ScientificWorldJournal 2013;2013:380797. [PMID: 23843733 DOI: 10.1155/2013/380797] [Cited by in Crossref: 3] [Cited by in F6Publishing: 8] [Article Influence: 0.3] [Reference Citation Analysis]
114 Cha H, Yoon HI, Lee IJ, Koom WS, Han KH, Seong J. Clinical factors related to recurrence after hepatic arterial concurrent chemoradiotherapy for advanced but liver-confined hepatocellular carcinoma. J Radiat Res. 2013;54:1069-1077. [PMID: 23633620 DOI: 10.1093/jrr/rrt034] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
115 Zubkova E, Semenkova L, Dudich E, Dudich I, Parfyonova Y, Menshikov M. Alpha-fetoprotein contributes to THP-1 cell invasion and chemotaxis via protein kinase and Gi-protein-dependent pathways. Mol Cell Biochem 2013;379:283-93. [PMID: 23615710 DOI: 10.1007/s11010-013-1650-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
116 Murillo A, Artigas V, González JA, Gallego A, Montserrat E, Rodriguez M, Trías M. Resección hepática por hepatocarcinoma: estudio comparativo entre pacientes menores y mayores de 70 años. Cirugía Española 2013;91:224-30. [DOI: 10.1016/j.ciresp.2012.07.016] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
117 Li GB, Zhang XL, Yuan L, Jiao QQ, Liu DJ, Liu J. Protein phosphatase magnesium-dependent 1δ (PPM1D) mRNA expression is a prognosis marker for hepatocellular carcinoma. PLoS One. 2013;8:e60775. [PMID: 23556002 DOI: 10.1371/journal.pone.0060775] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 1.7] [Reference Citation Analysis]
118 Shimada S, Kamiyama T, Yokoo H, Wakayama K, Tsuruga Y, Kakisaka T, Kamachi H, Taketomi A. Clinicopathological characteristics and prognostic factors in young patients after hepatectomy for hepatocellular carcinoma. World J Surg Oncol 2013;11:52. [PMID: 23452898 DOI: 10.1186/1477-7819-11-52] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
119 Fang Y, Fu D, Tang W, Cai Y, Ma D, Wang H, Xue R, Liu T, Huang X, Dong L, Wu H, Shen X. Ubiquitin C-terminal Hydrolase 37, a novel predictor for hepatocellular carcinoma recurrence, promotes cell migration and invasion via interacting and deubiquitinating PRP19. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research 2013;1833:559-72. [DOI: 10.1016/j.bbamcr.2012.11.020] [Cited by in Crossref: 41] [Cited by in F6Publishing: 41] [Article Influence: 4.6] [Reference Citation Analysis]
120 Hu SW, Zhang M, Xue L, Wen JM. Regulation effect of zinc fingers and homeoboxes 2 on alpha-fetoprotein in human hepatocellular carcinoma. Gastroenterol Res Pract 2013;2013:101083. [PMID: 23533382 DOI: 10.1155/2013/101083] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
121 Zhou J, Yan T, Bi X, Zhao H, Huang Z, Zhang Y, Li Y, Feng L, Wang J, Cai J. Evaluation of seven different staging systems for alpha-fetoprotein expression in hepatocellular carcinoma after hepatectomy. Tumour Biol. 2013;34:1061-1070. [PMID: 23322323 DOI: 10.1007/s13277-013-0646-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
122 Selimovic D, El-Khattouti A, Ghozlan H, Haikel Y, Abdelkader O, Hassan M. Hepatitis C virus-related hepatocellular carcinoma: An insight into molecular mechanisms and therapeutic strategies. World J Hepatol 2012; 4(12): 342-355 [PMID: 23355912 DOI: 10.4254/wjh.v4.i12.342] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 2.2] [Reference Citation Analysis]
123 Wang X, Wang Q, Lin H, Li S, Sun L, Yang Y. HSP72 and gp96 in gastroenterological cancers. Clin Chim Acta 2013;417:73-9. [PMID: 23266770 DOI: 10.1016/j.cca.2012.12.017] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
124 Wu X, Chen H, Gao Q, Bai J, Wang X, Zhou J, Qiu S, Xu Y, Shi Y, Wang X, Zhou J, Fan J. Downregulation of JWA promotes tumor invasion and predicts poor prognosis in human hepatocellular carcinoma. Mol Carcinog 2014;53:325-36. [PMID: 23169062 DOI: 10.1002/mc.21981] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
125 Clinkenbeard EL, Butler JE, Spear BT. Pericentral activity of alpha-fetoprotein enhancer 3 and glutamine synthetase upstream enhancer in the adult liver are regulated by β-catenin in mice. Hepatology 2012;56:1892-901. [PMID: 22544812 DOI: 10.1002/hep.25819] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
126 Carr BI, Guerra V, Pancoska P. Thrombocytopenia in relation to tumor size in patients with hepatocellular carcinoma. Oncology. 2012;83:339-345. [PMID: 23006937 DOI: 10.1159/000342431] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 2.2] [Reference Citation Analysis]
127 Zhu CB, Wang C, Chen LL, Ma GL, Zhang SC, Su L, Tian JJ, Gai ZT. Serum YKL-40 independently predicts outcome after transcatheter arterial chemoembolization of hepatocellular carcinoma. PLoS One 2012;7:e44648. [PMID: 22970277 DOI: 10.1371/journal.pone.0044648] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
128 Liu B, Zhang J, Huang C, Liu H. Dyskerin overexpression in human hepatocellular carcinoma is associated with advanced clinical stage and poor patient prognosis. PLoS One 2012;7:e43147. [PMID: 22912812 DOI: 10.1371/journal.pone.0043147] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 3.3] [Reference Citation Analysis]
129 Zheng Y, Yin L, Chen H, Yang S, Pan C, Lu S, Miao M, Jiao B. miR-376a suppresses proliferation and induces apoptosis in hepatocellular carcinoma. FEBS Lett. 2012;586:2396-2403. [PMID: 22684007 DOI: 10.1016/j.febslet.2012.05.054] [Cited by in Crossref: 52] [Cited by in F6Publishing: 45] [Article Influence: 5.2] [Reference Citation Analysis]
130 Hussein YM, Morad FE, Gameel MA, Emam WA, El Sawy WH, El Tarhouny SA, Bayomy ES, Raafat N. MAGE-4 gene m-RNA and TGF in blood as potential biochemical markers for HCC in HCV-infected patients.Med Oncol. 2012;29:3055-3062. [PMID: 22653756 DOI: 10.1007/s12032-012-0257-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
131 Wang X, Lin H, Wang Q, Gu Y. Specific Antitumor Immunity Induced by Cross-linking Complex Heat Shock Protein 72 and Alpha-fetoprotein. Cancer Biotherapy and Radiopharmaceuticals 2012;27:189-97. [DOI: 10.1089/cbr.2011.1135] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
132 Chon YE, Choi GH, Lee MH, Kim SU, Kim do Y, Ahn SH, Kim KS, Choi JS, Han KH, Chon CY. Combined measurement of preoperative α-fetoprotein and des-γ-carboxy prothrombin predicts recurrence after curative resection in patients with hepatitis-B-related hepatocellular carcinoma. Int J Cancer. 2012;131:2332-2341. [PMID: 22362471 DOI: 10.1002/ijc.27507] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 2.4] [Reference Citation Analysis]
133 Lin YH, Chiou YY, Chou YH, Chau GY, Wang HK, Chiang JH, Chang CY. Radiofrequency ablation for recurrent hepatocellular carcinoma in postresectional patients: prognostic factors analysis. Eur J Gastroenterol Hepatol 2011;23:1239-44. [PMID: 21941191 DOI: 10.1097/MEG.0b013e32834c5b13] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
134 Yu L, Dai Z, Wang Z, Fan J, Zhou J. Prognostic indicators for tumor recurrence after liver transplantation in hepatocellular carcinoma and related molecular targeted therapy. Oncology. 2011;81 Suppl 1:116-122. [PMID: 22212945 DOI: 10.1159/000333273] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
135 Richardson P, Duan Z, Kramer J, Davila JA, Tyson GL, El-Serag HB. Determinants of serum alpha-fetoprotein levels in hepatitis C-infected patients. Clin Gastroenterol Hepatol. 2012;10:428-433. [PMID: 22155556 DOI: 10.1016/j.cgh.2011.11.025] [Cited by in Crossref: 42] [Cited by in F6Publishing: 34] [Article Influence: 3.8] [Reference Citation Analysis]
136 Kwofie SK, Schaefer U, Sundararajan VS, Bajic VB, Christoffels A. HCVpro: Hepatitis C virus protein interaction database. Infection, Genetics and Evolution 2011;11:1971-7. [DOI: 10.1016/j.meegid.2011.09.001] [Cited by in Crossref: 53] [Cited by in F6Publishing: 52] [Article Influence: 4.8] [Reference Citation Analysis]
137 Wang L, Zhang Z, Wang FS. The efficacy of miRNA122, a novel therapeutic target, for predicting the progression of hepatocellular carcinoma (HCC). Cell Mol Immunol. 2012;9:103-104. [PMID: 21983871 DOI: 10.1038/cmi.2011.43] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
138 Qiu J, Huang P, Liu Q, Hong J, Li B, Lu C, Wang L, Wang J, Yuan Y. Identification of MACC1 as a novel prognostic marker in hepatocellular carcinoma. J Transl Med. 2011;9:166. [PMID: 21955323 DOI: 10.1186/1479-5876-9-166] [Cited by in Crossref: 57] [Cited by in F6Publishing: 55] [Article Influence: 5.2] [Reference Citation Analysis]
139 Singal AG, Chan V, Getachew Y, Guerrero R, Reisch JS, Cuthbert JA. Predictors of liver transplant eligibility for patients with hepatocellular carcinoma in a safety net hospital. Dig Dis Sci. 2012;57:580-586. [PMID: 21953138 DOI: 10.1007/s10620-011-1904-7] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 1.0] [Reference Citation Analysis]
140 Nakanishi M, Chuma M, Hige S, Omatsu T, Yokoo H, Nakanishi K, Kamiyama T, Kubota K, Haga H, Matsuno Y. Relationship between diffusion-weighted magnetic resonance imaging and histological tumor grading of hepatocellular carcinoma. Ann Surg Oncol. 2012;19:1302-1309. [PMID: 21927976 DOI: 10.1245/s10434-011-2066-8] [Cited by in Crossref: 90] [Cited by in F6Publishing: 98] [Article Influence: 8.2] [Reference Citation Analysis]
141 Kobayashi M, Hosaka T, Ikeda K, Seko Y, Kawamura Y, Sezaki H, Akuta N, Suzuki F, Suzuki Y, Saitoh S. Highly sensitive AFP-L3% assay is useful for predicting recurrence of hepatocellular carcinoma after curative treatment pre- and postoperatively. Hepatol Res. 2011;41:1036-1045. [PMID: 21883741 DOI: 10.1111/j.1872-034x.2011.00858.x] [Cited by in Crossref: 40] [Cited by in F6Publishing: 20] [Article Influence: 3.6] [Reference Citation Analysis]
142 Tyson GL, Duan Z, Kramer JR, Davila JA, Richardson PA, El-Serag HB. Level of α-fetoprotein predicts mortality among patients with hepatitis C-related hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2011;9:989-994. [PMID: 21820396 DOI: 10.1016/j.cgh.2011.07.026] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 3.0] [Reference Citation Analysis]
143 Takaki H, Yamakado K, Sakurai H, Nakatsuka A, Shiraki K, Isaji S, Takeda K. Radiofrequency Ablation Combined With Chemoembolization: Treatment of Recurrent Hepatocellular Carcinomas After Hepatectomy. American Journal of Roentgenology 2011;197:488-94. [DOI: 10.2214/ajr.10.4933] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
144 Fielding L. Current imaging strategies of primary and secondary neoplasms of the liver. Semin Intervent Radiol 2006;23:3-12. [PMID: 21326715 DOI: 10.1055/s-2006-939836] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
145 Cha HJ, Kim J, Hong SM, Hong SJ, Park JH, Kim E, Wang H, Choi YJ, Do I, Joh JW, Kim DS, Choi KY. Overexpression of Renal Tumor Antigen Is Associated with Tumor Invasion and Poor Prognosis of Hepatocellular Carcinoma. Ann Surg Oncol 2012;19:404-11. [DOI: 10.1245/s10434-011-1856-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
146 Yuan RH, Jeng YM, Hu RH, Lai PL, Lee PH, Cheng CC, Hsu HC. Role of p53 and β-catenin mutations in conjunction with CK19 expression on early tumor recurrence and prognosis of hepatocellular carcinoma. J Gastrointest Surg. 2011;15:321-329. [PMID: 21061181 DOI: 10.1007/s11605-010-1373-x] [Cited by in Crossref: 43] [Cited by in F6Publishing: 35] [Article Influence: 3.9] [Reference Citation Analysis]
147 Kojima K, Takata A, Vadnais C, Otsuka M, Yoshikawa T, Akanuma M, Kondo Y, Kang YJ, Kishikawa T, Kato N. MicroRNA122 is a key regulator of α-fetoprotein expression and influences the aggressiveness of hepatocellular carcinoma. Nat Commun. 2011;2:338. [PMID: 21654638 DOI: 10.1038/ncomms1345] [Cited by in Crossref: 75] [Cited by in F6Publishing: 71] [Article Influence: 6.8] [Reference Citation Analysis]
148 Chen XH, Zhang BH, Xin Y, Ren ZG, Fan J, Qiu SJ, Zhou J. Risk factors for residual tumor after resection of hepatocellular carcinoma. World J Gastroenterol 2011; 17(14): 1889-1894 [PMID: 21528064 DOI: 10.3748/wjg.v17.i14.1889] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
149 Yang M, Guo Z, Li BG. Risk factors for early recurrence after cryoablation for hepatocellular carcinoma. Shijie Huaren Xiaohua Zazhi 2011; 19(9): 960-963 [DOI: 10.11569/wcjd.v19.i9.960] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
150 Kobashi H, Miyake Y, Ikeda F, Yasunaka T, Nishino K, Moriya A, Kubota J, Nakamura S, Takaki A, Nouso K, Yamada G, Yamamoto K. Long-term outcome and hepatocellular carcinoma development in chronic hepatitis B or cirrhosis patients after nucleoside analog treatment with entecavir or lamivudine. Hepatol Res 2011;41:405-16. [PMID: 21435126 DOI: 10.1111/j.1872-034X.2011.00785.x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
151 Ataide EC, Machado RR, Ribeiro MBC, Mattosinho TJAP, Romani FA, Escanhonela CAF, Boin IDFSF. Correlação do nível de alfa-feto proteína, índice de sobrevida e recidiva tumoral em pacientes submetidosa transplante hepático. ABCD, arq bras cir dig 2011;24:43-7. [DOI: 10.1590/s0102-67202011000100009] [Cited by in Crossref: 3] [Article Influence: 0.3] [Reference Citation Analysis]
152 Peterson ML, Ma C, Spear BT. Zhx2 and Zbtb20: novel regulators of postnatal alpha-fetoprotein repression and their potential role in gene reactivation during liver cancer. Semin Cancer Biol. 2011;21:21-27. [PMID: 21216289 DOI: 10.1016/j.semcancer.2011.01.001] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 2.5] [Reference Citation Analysis]
153 Carr BI, Pancoska P, Branch RA. Low alpha-fetoprotein hepatocellular carcinoma. J Gastroenterol Hepatol. 2010;25:1543-1549. [PMID: 20796153 DOI: 10.1111/j.1440-1746.2010.06303.x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 2.0] [Reference Citation Analysis]
154 Tseng PL, Wang JH, Tung HD, Hung CH, Kee KM, Chen CH, Chang KC, Lee CM, Changchien CS, Chen PF. Optimal treatment increased survival of hepatocellular carcinoma patients detected with community-based screening. J Gastroenterol Hepatol. 2010;25:1426-1434. [PMID: 20659234 DOI: 10.1111/j.1440-1746.2010.06285.x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 2.1] [Reference Citation Analysis]
155 Shao YY, Lin ZZ, Hsu C, Shen YC, Hsu CH, Cheng AL. Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma. Cancer. 2010;116:4590-4596. [PMID: 20572033 DOI: 10.1002/cncr.25257] [Cited by in Crossref: 110] [Cited by in F6Publishing: 106] [Article Influence: 9.2] [Reference Citation Analysis]
156 Lin ZZ, Jeng YM, Hu FC, Pan HW, Tsao HW, Lai PL, Lee PH, Cheng AL, Hsu HC. Significance of Aurora B overexpression in hepatocellular carcinoma. Aurora B Overexpression in HCC. BMC Cancer. 2010;10:461. [PMID: 20799978 DOI: 10.1186/1471-2407-10-461] [Cited by in Crossref: 61] [Cited by in F6Publishing: 71] [Article Influence: 5.1] [Reference Citation Analysis]
157 Li JC, Yang XR, Sun HX, Xu Y, Zhou J, Qiu SJ, Ke AW, Cui YH, Wang ZJ, Wang WM. Up-regulation of Krüppel-like factor 8 promotes tumor invasion and indicates poor prognosis for hepatocellular carcinoma. Gastroenterology. 2010;139:2146-2157.e12. [PMID: 20728449 DOI: 10.1053/j.gastro.2010.08.004] [Cited by in Crossref: 65] [Cited by in F6Publishing: 65] [Article Influence: 5.4] [Reference Citation Analysis]
158 Hsieh CB, Chen TW, Chu CM, Chu HC, Yu CP, Chung KP. Is inconsistency of α-fetoprotein level a good prognosticator for hepatocellular carcinoma recurrence? World J Gastroenterol 2010; 16(24): 3049-3055 [PMID: 20572309 DOI: 10.3748/wjg.v16.i24.3049] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
159 Lee NP, Cheung ST, Poon RT, Fan ST, Luk JM. Genomic and proteomic biomarkers for diagnosis and prognosis of hepatocellular carcinoma. Biomark Med 2007;1:273-84. [PMID: 20477402 DOI: 10.2217/17520363.1.2.273] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
160 Miura N, Osaki Y, Nagashima M, Kohno M, Yorozu K, Shomori K, Kanbe T, Oyama K, Kishimoto Y, Maruyama S. A novel biomarker TERTmRNA is applicable for early detection of hepatoma. BMC Gastroenterol. 2010;10:46. [PMID: 20482774 DOI: 10.1186/1471-230x-10-46] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
161 Carr BI, Pancoska P, Branch RA. HCC in Older Patients. Dig Dis Sci 2010;55:3584-90. [DOI: 10.1007/s10620-010-1177-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
162 Kilickap S, Arslan C, Senel S, Ataseven H. Alpha-fetoprotein response after locoregional therapy for hepatocellular carcinoma. J Clin Oncol 2010;28:e99; author reply e100. [PMID: 20085931 DOI: 10.1200/JCO.2009.26.7070] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
163 Chan SL, Chan AT, Yeo W. Role of alpha-fetoprotein in hepatocellular carcinoma: prognostication, treatment monitoring or both? Future Oncol. 2009;5:889-899. [PMID: 19663737 DOI: 10.2217/fon.09.64] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 1.8] [Reference Citation Analysis]
164 Lin C, Kuo C, Lu C, Wu M, Huang RS. Elevated Serum Vitamin B 12 Levels in Association With Tumor Markers as the Prognostic Factors Predictive for Poor Survival in Patients With Hepatocellular Carcinoma. Nutrition and Cancer 2010;62:190-7. [DOI: 10.1080/01635580903305334] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
165 Ge L, Zhang JG, Samathanam CA, Delgado C, Tarbiyat-Boldaji M, Dan Q, Hoa N, Nguyen TV, Alipanah R, Pham JT, Sanchez R, Wepsic HT, Morgan TR, Jadus MR. Cytotoxic T cell immunity against the non-immunogenic, murine, hepatocellular carcinoma Hepa1-6 is directed towards the novel alternative form of macrophage colony stimulating factor. Cell Immunol 2009;259:117-27. [PMID: 19615673 DOI: 10.1016/j.cellimm.2009.06.008] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
166 Ren J, He W, Zhang R, Li Z, Cao W, Yao J, Zhu F, Zhang T, Wu G. RASSF2A promoter methylation in hepatitis B virus-related hepatocellular carcinogenesis and its correlation with elevated serum α-fetoprotein level. J Huazhong Univ Sci Technol [Med Sci ] 2009;29:309-12. [DOI: 10.1007/s11596-009-0309-8] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
167 Huang J, Li BK, Chen GH, Li JQ, Zhang YQ, Li GH, Yuan YF. Long-term outcomes and prognostic factors of elderly patients with hepatocellular carcinoma undergoing hepatectomy. J Gastrointest Surg. 2009;13:1627-1635. [PMID: 19506976 DOI: 10.1007/s11605-009-0933-4] [Cited by in Crossref: 80] [Cited by in F6Publishing: 77] [Article Influence: 6.2] [Reference Citation Analysis]
168 Yin X, Xie X, Lu M, Xu H, Xu Z, Kuang M, Liu G, Liang J, Lau WY. Percutaneous thermal ablation of medium and large hepatocellular carcinoma: Long-term outcome and prognostic factors. Cancer 2009;115:1914-23. [DOI: 10.1002/cncr.24196] [Cited by in Crossref: 100] [Cited by in F6Publishing: 103] [Article Influence: 7.7] [Reference Citation Analysis]
169 Marrero JA, Welling T. Modern Diagnosis and Management of Hepatocellular Carcinoma. Clinics in Liver Disease 2009;13:233-47. [DOI: 10.1016/j.cld.2009.02.007] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 2.1] [Reference Citation Analysis]
170 Nanashima A, Sumida Y, Tobinaga S, Shibata K, Shindo H, Obatake M, Shibasaki S, Ide N, Nagayasu T. Postoperative changes in protein-induced vitamin K absence or antagonist II levels after hepatectomy in patients with hepatocellular carcinoma: relationship to prognosis. HPB (Oxford). 2006;8:137-141. [PMID: 18333262 DOI: 10.1080/13651820500273475] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
171 Cui W, Gu F, Hu KQ. Effects and mechanisms of silibinin on human hepatocellular carcinoma xenografts in nude mice. World J Gastroenterol 2009; 15(16): 1943-1950 [PMID: 19399925 DOI: 10.3748/wjg.15.1943] [Cited by in CrossRef: 45] [Cited by in F6Publishing: 41] [Article Influence: 3.5] [Reference Citation Analysis]
172 Ju MJ, Qiu SJ, Fan J, Zhou J, Gao Q, Cai MY, Li YW, Tang ZY. Preoperative serum gamma-glutamyl transferase to alanine aminotransferase ratio is a convenient prognostic marker for Child-Pugh A hepatocellular carcinoma after operation. J Gastroenterol. 2009;44:635-642. [PMID: 19387533 DOI: 10.1007/s00535-009-0050-x] [Cited by in Crossref: 42] [Cited by in F6Publishing: 41] [Article Influence: 3.2] [Reference Citation Analysis]
173 Hu J, Xu Y, Shen ZZ, Wang Z, Lu Q, Yang GH, Ding ZB, Fan J, Zhou J. High expressions of vascular endothelial growth factor and platelet-derived endothelial cell growth factor predict poor prognosis in alpha-fetoprotein-negative hepatocellular carcinoma patients after curative resection. J Cancer Res Clin Oncol. 2009;135:1359-1367. [PMID: 19350273 DOI: 10.1007/s00432-009-0577-5] [Cited by in Crossref: 11] [Cited by in F6Publishing: 16] [Article Influence: 0.8] [Reference Citation Analysis]
174 Cieply B, Zeng G, Proverbs-Singh T, Geller DA, Monga SP. Unique phenotype of hepatocellular cancers with exon-3 mutations in beta-catenin gene. Hepatology 2009;49:821-31. [PMID: 19101982 DOI: 10.1002/hep.22695] [Cited by in Crossref: 114] [Cited by in F6Publishing: 102] [Article Influence: 8.8] [Reference Citation Analysis]
175 Takigawa Y, Brown AM. Wnt signaling in liver cancer. Curr Drug Targets. 2008;9:1013-1024. [PMID: 18991612 DOI: 10.2174/138945008786786127] [Cited by in Crossref: 103] [Cited by in F6Publishing: 98] [Article Influence: 7.9] [Reference Citation Analysis]
176 Kaibori M, Ishizaki M, Saito T, Matsui K, Kwon AH, Kamiyama Y. Risk factors and outcome of early recurrence after resection of small hepatocellular carcinomas. Am J Surg. 2009;198:39-45. [PMID: 19178896 DOI: 10.1016/j.amjsurg.2008.07.051] [Cited by in Crossref: 36] [Cited by in F6Publishing: 37] [Article Influence: 2.8] [Reference Citation Analysis]
177 Cui W, Hu SX, Tang ZY, Hu KQ. In-vivo effects and mechanisms of celecoxib-reduced growth of cyclooxygenase-2 (COX-2)-expressing versus COX-2-deleted human HCC xenografts in nude mice. Anticancer Drugs. 2008;19:891-897. [PMID: 18766003 DOI: 10.1097/CAD.0b013e32830ef8ca] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
178 Yu B, Yang X, Xu Y, Yao G, Shu H, Lin B, Hood L, Wang H, Yang S, Gu J. Elevated expression of DKK1 is associated with cytoplasmic/nuclear beta-catenin accumulation and poor prognosis in hepatocellular carcinomas. J Hepatol. 2009;50:948-957. [PMID: 19303159 DOI: 10.1016/j.jhep.2008.11.020] [Cited by in Crossref: 91] [Cited by in F6Publishing: 92] [Article Influence: 7.0] [Reference Citation Analysis]
179 Park UJ, Kim YH, Kang KJ, Lim TJ. [Risk factors for early recurrence after surgical resection for hepatocellular carcinoma]. Korean J Hepatol. 2008;14:371-380. [PMID: 18815460 DOI: 10.3350/kjhep.2008.14.3.371] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 0.7] [Reference Citation Analysis]
180 Cieply B, Zeng G, Proverbs-Singh T, Geller DA, Monga SP. Unique phenotype of hepatocellular cancers with exon-3 mutations in beta-catenin gene. Hepatology 2009;49:821-31. [PMID: 19101982 DOI: 10.1002/hep.22695] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
181 Miura N, Hasegawa J, Shiota G. Serum messenger RNA as a biomarker and its clinical usefulness in malignancies. Clin Med Oncol 2008;2:511-27. [PMID: 21892326 DOI: 10.4137/cmo.s379] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
182 Ko CY, Hsu HC, Shen MR, Chang WC, Wang JM. Epigenetic silencing of CCAAT/enhancer-binding protein delta activity by YY1/polycomb group/DNA methyltransferase complex. J Biol Chem 2008;283:30919-32. [PMID: 18753137 DOI: 10.1074/jbc.M804029200] [Cited by in Crossref: 60] [Cited by in F6Publishing: 48] [Article Influence: 4.3] [Reference Citation Analysis]
183 Murugavel KG, Mathews S, Jayanthi V, Shankar EM, Hari R, Surendran R, Vengatesan A, Raghuram K, Rajasambandam P, Murali A, Srinivas U, Palaniswamy KR, Pugazhendhi T, Thyagarajan SP. Alpha-fetoprotein as a tumor marker in hepatocellular carcinoma: investigations in south Indian subjects with hepatotropic virus and aflatoxin etiologies. Int J Infect Dis 2008;12:e71-6. [PMID: 18658001 DOI: 10.1016/j.ijid.2008.04.010] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 1.3] [Reference Citation Analysis]
184 Sun Y, Mi W, Cai J, Ying W, Liu F, Lu H, Qiao Y, Jia W, Bi X, Lu N. Quantitative proteomic signature of liver cancer cells: tissue transglutaminase 2 could be a novel protein candidate of human hepatocellular carcinoma. J Proteome Res. 2008;7:3847-3859. [PMID: 18646787 DOI: 10.1021/pr800153s] [Cited by in Crossref: 52] [Cited by in F6Publishing: 54] [Article Influence: 3.7] [Reference Citation Analysis]
185 Mitsuhashi N, Kobayashi S, Doki T, Kimura F, Shimizu H, Yoshidome H, Ohtsuka M, Kato A, Yoshitomi H, Nozawa S. Clinical significance of alpha-fetoprotein: involvement in proliferation, angiogenesis, and apoptosis of hepatocellular carcinoma. J Gastroenterol Hepatol. 2008;23:e189-e197. [PMID: 18466288 DOI: 10.1111/j.1440-1746.2008.05340.x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 34] [Article Influence: 2.1] [Reference Citation Analysis]
186 Mourad W, Khalaf H, Tulbah A, Al Omari M, Al Mana H, Neimatallah M. Clinicopathologic features of hepatic neoplasms in explanted livers: a single institution experience. Ann Saudi Med 2007;27:437-41. [PMID: 18059117 DOI: 10.5144/0256-4947.2007.437] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
187 Sakata J, Shirai Y, Wakai T, Kaneko K, Nagahashi M, Hatakeyama K. Preoperative predictors of vascular invasion in hepatocellular carcinoma. Eur J Surg Oncol. 2008;34:900-905. [PMID: 18343084 DOI: 10.1016/j.ejso.2008.01.031] [Cited by in Crossref: 65] [Cited by in F6Publishing: 61] [Article Influence: 4.6] [Reference Citation Analysis]
188 Lin CY, Kee KM, Wang JH, Lee CM, Chen CL, Changchien CS, Hu TH, Cheng YF, Hsu HC, Wang CC. Is the Cancer of the Liver Italian Program system an adequate weighting for survival of hepatocellular carcinoma? Evaluation of intrascore prognostic value among 36 subgroups. Liver Int. 2009;29:74-81. [PMID: 18331238 DOI: 10.1111/j.1478-3231.2008.01702.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 1.5] [Reference Citation Analysis]
189 Verhoef C, van Dekken H, Hofland L, Zondervan P, de Wilt J, van Marion R, de Man R, Ijzermans J, van Eijck C. Somatostatin Receptor in Human Hepatocellular Carcinomas: Biological, Patient and Tumor Characteristics. Dig Surg 2008;25:21-6. [DOI: 10.1159/000117819] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
190 Zhang HK, Pan K, Wang H, Weng DS, Song HF, Zhou J, Huang W, Li JJ, Chen MS, Xia JC. Decreased expression of ING2 gene and its clinicopathological significance in hepatocellular carcinoma. Cancer Lett. 2008;261:183-192. [PMID: 18160212 DOI: 10.1016/j.canlet.2007.11.019] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 2.3] [Reference Citation Analysis]
191 Miura N, Maruyama S, Oyama K, Horie Y, Kohno M, Noma E, Sakaguchi S, Nagashima M, Kudo M, Kishimoto Y, Kawasaki H, Hasegawa J, Shiota G. Development of a Novel Assay to Quantify Serum Human Telomerase Reverse Transcriptase Messenger RNA and Its Significance as a Tumor Marker for Hepatocellular Carcinoma. Oncology 2007;72:45-51. [DOI: 10.1159/000111706] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.1] [Reference Citation Analysis]
192 Sun H, Zhang W, Qin L, Zhang B, Ye Q, Wang L, Ren N, Zhuang P, Zhu X, Fan J, Tang Z. Positive serum hepatitis B e antigen is associated with higher risk of early recurrence and poorer survival in patients after curative resection of hepatitis B-related hepatocellular carcinoma. Journal of Hepatology 2007;47:684-90. [DOI: 10.1016/j.jhep.2007.06.019] [Cited by in Crossref: 125] [Cited by in F6Publishing: 120] [Article Influence: 8.3] [Reference Citation Analysis]
193 Lah JJ, Cui W, Hu KQ. Effects and mechanisms of silibinin on human hepatoma cell lines. World J Gastroenterol 2007; 13(40): 5299-5305 [PMID: 17879397 DOI: 10.3748/wjg.v13.i40.5299] [Cited by in CrossRef: 65] [Cited by in F6Publishing: 60] [Article Influence: 4.3] [Reference Citation Analysis]
194 Shih YL, Hsieh CB, Lai HC, Yan MD, Hsieh TY, Chao YC, Lin YW. SFRP1 suppressed hepatoma cells growth through Wnt canonical signaling pathway. Int J Cancer. 2007;121:1028-1035. [PMID: 17443492 DOI: 10.1002/ijc.22750] [Cited by in Crossref: 65] [Cited by in F6Publishing: 59] [Article Influence: 4.3] [Reference Citation Analysis]
195 Schwartz M, Roayaie S, Konstadoulakis M. Strategies for the management of hepatocellular carcinoma. Nat Clin Pract Oncol. 2007;4:424-432. [PMID: 17597707 DOI: 10.1038/ncponc0844] [Cited by in Crossref: 191] [Cited by in F6Publishing: 179] [Article Influence: 12.7] [Reference Citation Analysis]
196 Zhang Q, Zhou J, Ku X, Chen X, Zhang L, Xu J, Chen G, Li Q, Qian F, Tian R, Wen N, Chen Z. Expression of CD147 as a significantly unfavorable prognostic factor in hepatocellular carcinoma. European Journal of Cancer Prevention 2007;16:196-202. [DOI: 10.1097/01.cej.0000236245.40619.c3] [Cited by in Crossref: 40] [Cited by in F6Publishing: 34] [Article Influence: 2.7] [Reference Citation Analysis]
197 Yokoo H, Kondo T, Okano T, Nakanishi K, Sakamoto M, Kosuge T, Todo S, Hirohashi S. Protein expression associated with early intrahepatic recurrence of hepatocellular carcinoma after curative surgery. Cancer Sci. 2007;98:665-673. [PMID: 17391314 DOI: 10.1111/j.1349-7006.2007.00441.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 1.2] [Reference Citation Analysis]
198 Zhou L, Rui JA, Wang SB, Chen SG, Qu Q, Chi TY, Wei X, Han K, Zhang N, Zhao HT. Factors predictive for long-term survival of male patients with hepatocellular carcinoma after curative resection. J Surg Oncol. 2007;95:298-303. [PMID: 17326130 DOI: 10.1002/jso.20678] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 1.6] [Reference Citation Analysis]
199 Yang SH, Suh KS, Lee HW, Cho EH, Cho JY, Cho YB, Kim IH, Yi NJ, Lee KU. A revised scoring system utilizing serum alphafetoprotein levels to expand candidates for living donor transplantation in hepatocellular carcinoma. Surgery. 2007;141:598-609. [PMID: 17462459 DOI: 10.1016/j.surg.2006.11.006] [Cited by in Crossref: 81] [Cited by in F6Publishing: 77] [Article Influence: 5.4] [Reference Citation Analysis]
200 Lee YC, Pan HW, Peng SY, Lai PL, Kuo WS, Ou YH, Hsu HC. Overexpression of tumour-associated trypsin inhibitor (TATI) enhances tumour growth and is associated with portal vein invasion, early recurrence and a stage-independent prognostic factor of hepatocellular carcinoma. Eur J Cancer. 2007;43:736-744. [PMID: 17267202 DOI: 10.1016/j.ejca.2006.11.020] [Cited by in Crossref: 40] [Cited by in F6Publishing: 43] [Article Influence: 2.7] [Reference Citation Analysis]
201 Wakai T, Shirai Y, Sakata J, Kaneko K, Cruz PV, Akazawa K, Hatakeyama K. Anatomic resection independently improves long-term survival in patients with T1-T2 hepatocellular carcinoma. Ann Surg Oncol. 2007;14:1356-1365. [PMID: 17252289 DOI: 10.1245/s10434-006-9318-z] [Cited by in Crossref: 130] [Cited by in F6Publishing: 121] [Article Influence: 8.7] [Reference Citation Analysis]
202 Sun Y, Lin R, Dai J, Jin D, Wang SQ. Suppression of tumor growth using antisense oligonucleotide against survivin in an orthotopic transplant model of human hepatocellular carcinoma in nude mice. Oligonucleotides 2006;16:365-74. [PMID: 17155911 DOI: 10.1089/oli.2006.16.365] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
203 Chen CH, Su WW, Yang SS, Chang TT, Cheng KS, Lin HH, Wu SS, Lee CM, Changchien CS, Chen CJ. Long-term trends and geographic variations in the survival of patients with hepatocellular carcinoma: analysis of 11,312 patients in Taiwan. J Gastroenterol Hepatol. 2006;21:1561-1566. [PMID: 16928217 DOI: 10.1111/j.1440-1746.2006.04425.x] [Cited by in Crossref: 46] [Cited by in F6Publishing: 48] [Article Influence: 3.1] [Reference Citation Analysis]
204 Tian Z, Shen J, Moseman AP, Yang Q, Yang J, Xiao P, Wu E, Kohane IS. Dulxanthone A induces cell cycle arrest and apoptosisvia up-regulation of p53 through mitochondrial pathway in HepG2 cells. Int J Cancer 2008;122:31-8. [DOI: 10.1002/ijc.23048] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 1.7] [Reference Citation Analysis]
205 Wang X, Zhou Y, Ying X, Guo L, Zhao Y, Fang Y. Interaction between heat shock protein 72 and alpha-fetoprotein in human hepatocellular carcinomas. Clin Chim Acta 2007;379:158-62. [PMID: 17250819 DOI: 10.1016/j.cca.2006.12.015] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
206 Kuo SW, Chang YL, Huang PM, Hsu HH, Chen JS, Lee JM, Lee PH, Lee YC. Prognostic factors for pulmonary metastasectomy in hepatocellular carcinoma. Ann Surg Oncol. 2007;14:992-997. [PMID: 17151787 DOI: 10.1245/s10434-006-9217-3] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 1.8] [Reference Citation Analysis]
207 Huo T, Lee S. Role of the model for end-stage liver disease and serum ?-fetoprotein as prognostic predictors for hepatocellular carcinoma. Liver Int 2006;26:1300-1. [DOI: 10.1111/j.1478-3231.2006.01379.x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
208 Cheung ST, Liu CL, Chow JP, Lee YT, Ip YC, Ho JC, Fan ST. Preoperative plasma transcript AA454543 level is an independent prognostic factor for hepatocellular carcinoma after partial hepatectomy. Neoplasia 2006;8:696-701. [PMID: 16984726 DOI: 10.1593/neo.06181] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
209 Farazi PA, DePinho RA. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer. 2006;6:674-687. [PMID: 16929323 DOI: 10.1038/nrc1934] [Cited by in Crossref: 1337] [Cited by in F6Publishing: 1312] [Article Influence: 83.6] [Reference Citation Analysis]
210 Yuan RH, Jeng YM, Chen HL, Lai PL, Pan HW, Hsieh FJ, Lin CY, Lee PH, Hsu HC. Stathmin overexpression cooperates with p53 mutation and osteopontin overexpression, and is associated with tumour progression, early recurrence, and poor prognosis in hepatocellular carcinoma. J Pathol. 2006;209:549-558. [PMID: 16739096 DOI: 10.1002/path.2011] [Cited by in Crossref: 105] [Cited by in F6Publishing: 111] [Article Influence: 6.6] [Reference Citation Analysis]
211 Durnez A, Verslype C, Nevens F, Fevery J, Aerts R, Pirenne J, Lesaffre E, Libbrecht L, Desmet V, Roskams T. The clinicopathological and prognostic relevance of cytokeratin 7 and 19 expression in hepatocellular carcinoma. A possible progenitor cell origin. Histopathology. 2006;49:138-151. [PMID: 16879391 DOI: 10.1111/j.1365-2559.2006.02468.x] [Cited by in Crossref: 268] [Cited by in F6Publishing: 245] [Article Influence: 16.8] [Reference Citation Analysis]
212 El Far MA, Atwa MA, Yahya RS, El Basuni MA. Evaluation of serum levels of p53 in hepatocellular carcinoma in Egypt. Clin Chem Lab Med. 2006;44:653-656. [PMID: 16681440 DOI: 10.1515/cclm.2006.091] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
213 Zhou L, Rui JA, Wang SB, Chen SG, Qu Q, Chi TY, Wei X, Han K, Zhang N, Zhao HT. Clinicopathological features, post-surgical survival and prognostic indicators of elderly patients with hepatocellular carcinoma. Eur J Surg Oncol. 2006;32:767-772. [PMID: 16725304 DOI: 10.1016/j.ejso.2006.03.050] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 1.7] [Reference Citation Analysis]
214 Farinati F, Marino D, De Giorgio M, Baldan A, Cantarini M, Cursaro C, Rapaccini G, Del Poggio P, Di Nolfo MA, Benvegnù L, Zoli M, Borzio F, Bernardi M, Trevisani F. Diagnostic and prognostic role of alpha-fetoprotein in hepatocellular carcinoma: both or neither? Am J Gastroenterol 2006;101:524-32. [PMID: 16542289 DOI: 10.1111/j.1572-0241.2006.00443.x] [Cited by in Crossref: 253] [Cited by in F6Publishing: 252] [Article Influence: 15.8] [Reference Citation Analysis]
215 Kemmer N, Neff G, Kaiser T, Zacharias V, Thomas M, Tevar A, Satwah S, Shukla R, Buell J. An analysis of the UNOS liver transplant registry: High serum alpha-fetoprotein does not justify an increase in MELD points for suspected hepatocellular carcinoma. Liver Transpl 2006;12:1519-22. [DOI: 10.1002/lt.20859] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
216 Shah SA, Greig PD, Gallinger S, Cattral MS, Dixon E, Kim RD, Taylor BR, Grant DR, Vollmer CM. Factors associated with early recurrence after resection for hepatocellular carcinoma and outcomes. J Am Coll Surg. 2006;202:275-283. [PMID: 16427553 DOI: 10.1016/j.jamcollsurg.2005.10.005] [Cited by in Crossref: 160] [Cited by in F6Publishing: 161] [Article Influence: 9.4] [Reference Citation Analysis]
217 Tsujita E, Taketomi A, Gion T, Kuroda Y, Endo K, Watanabe A, Nakashima H, Aishima S, Kohnoe S, Maehara Y. Suppressed MKP-1 is an independent predictor of outcome in patients with hepatocellular carcinoma. Oncology. 2005;69:342-347. [PMID: 16293973 DOI: 10.1159/000089766] [Cited by in Crossref: 39] [Cited by in F6Publishing: 32] [Article Influence: 2.3] [Reference Citation Analysis]
218 Lu MD, Yin XY, Xie XY, Xu HX, Xu ZF, Liu GJ, Kuang M, Zheng YL. Percutaneous thermal ablation for recurrent hepatocellular carcinoma after hepatectomy. Br J Surg. 2005;92:1393-1398. [PMID: 16044409 DOI: 10.1002/bjs.5102] [Cited by in Crossref: 45] [Cited by in F6Publishing: 48] [Article Influence: 2.6] [Reference Citation Analysis]
219 Wang XP, Wang QX, Li HY, Chen RF. Heat shock protein 70 chaperoned alpha-fetoprotein in human hepatocellular carcinoma cell line BEL-7402. World J Gastroenterol 2005; 11(35): 5561-5564 [PMID: 16222756 DOI: 10.3748/wjg.v11.i35.5561] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]